These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinicopathological features and outcomes of kidney allografts in plasma cell-rich acute rejection: A case series. Hamada AM; Yamamoto I; Kawabe M; Katsumata H; Yamakawa T; Katsuma A; Nakada Y; Kobayashi A; Koike Y; Miki J; Yamada H; Kimura T; Tanno Y; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T Nephrology (Carlton); 2018 Jul; 23 Suppl 2():22-26. PubMed ID: 29968414 [TBL] [Abstract][Full Text] [Related]
3. Clinical and Pathological Features of Plasma Cell-Rich Acute Rejection After Kidney Transplantation. Hasegawa J; Honda K; Omoto K; Wakai S; Shirakawa H; Okumi M; Ishida H; Fuchinoue S; Hattori M; Tanabe K Transplantation; 2018 May; 102(5):853-859. PubMed ID: 29319615 [TBL] [Abstract][Full Text] [Related]
4. The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies. Meehan SM; Domer P; Josephson M; Donoghue M; Sadhu A; Ho LT; Aronson AJ; Thistlethwaite JR; Haas M Hum Pathol; 2001 Feb; 32(2):205-15. PubMed ID: 11230708 [TBL] [Abstract][Full Text] [Related]
5. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224 [TBL] [Abstract][Full Text] [Related]
6. Acute rejection and graft survival in renal transplanted patients with viral diseases. Aiello FB; Calabrese F; Rigotti P; Furian L; Marino S; Cusinato R; Valente M Mod Pathol; 2004 Feb; 17(2):189-96. PubMed ID: 14657951 [TBL] [Abstract][Full Text] [Related]
7. Plasma cell-rich related acute rejection in kidney transplant: A case report and review of the literature. Tsai YY; Lim LM; Kuo HT; Tsai YC Medicine (Baltimore); 2022 Sep; 101(36):e30493. PubMed ID: 36086682 [TBL] [Abstract][Full Text] [Related]
8. Immunohistological study of a pediatric patient with plasma cell-rich acute rejection. Chikamoto H; Sugawara N; Akioka Y; Shimizu T; Horita S; Honda K; Moriyama T; Koike J; Yamaguchi Y; Hattori M Clin Transplant; 2012 Jul; 26 Suppl 24():54-7. PubMed ID: 22747477 [TBL] [Abstract][Full Text] [Related]
9. Plasma cell-rich acute rejections in living-related kidney transplantation: a clinicopathological study of 50 cases. Abbas K; Mubarak M; Zafar MN; Aziz T; Abbas H; Muzaffar R; Rizvi SA Clin Transplant; 2015 Sep; 29(9):835-41. PubMed ID: 26172154 [TBL] [Abstract][Full Text] [Related]
11. Renal graft loss with plasma cell-rich acute rejection in cadaveric renal transplantation: a case report. Suzuki T; Fukuzawa J; Furuya S; Yuzawa K; Aita K; Ohkohchi N; Nagata M Clin Transplant; 2005; 19 Suppl 14():71-5. PubMed ID: 15955173 [TBL] [Abstract][Full Text] [Related]
12. Allograft outcomes of treated children with kidney transplant who developed plasma cell-rich acute rejection (PCAR): A single center's experience. Alhamoud I; Huang R; Lacelle C; Burguete D; Hendricks AR; Torrealba JR; Seikaly MG Pediatr Transplant; 2019 Sep; 23(6):e13500. PubMed ID: 31437388 [TBL] [Abstract][Full Text] [Related]
13. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Pirsch JD; Miller J; Deierhoi MH; Vincenti F; Filo RS Transplantation; 1997 Apr; 63(7):977-83. PubMed ID: 9112351 [TBL] [Abstract][Full Text] [Related]
14. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Solez K; Vincenti F; Filo RS Transplantation; 1998 Dec; 66(12):1736-40. PubMed ID: 9884269 [TBL] [Abstract][Full Text] [Related]
15. The role of C4d immunostaining in the evaluation of the causes of renal allograft dysfunction. Ranjan P; Nada R; Jha V; Sakhuja V; Joshi K Nephrol Dial Transplant; 2008 May; 23(5):1735-41. PubMed ID: 18065805 [TBL] [Abstract][Full Text] [Related]
16. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. Jevnikar A; Arlen D; Barrett B; Boucher A; Cardella C; Cockfield SM; Rush D; Paraskevas S; Shapiro J; Shoker A; Yilmaz S; Zaltzman JS; Kiberd B Transplantation; 2008 Oct; 86(7):953-60. PubMed ID: 18852662 [TBL] [Abstract][Full Text] [Related]
17. Effect of early cyclosporine levels on kidney allograft rejection. Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683 [TBL] [Abstract][Full Text] [Related]
18. The correlation of Banff scoring with reversibility of first and recurrent rejection episodes. Gaber LW; Schroeder TJ; Moore LW; Shakouh-Amiri MH; Gaber AO Transplantation; 1996 Jun; 61(12):1711-5. PubMed ID: 8685948 [TBL] [Abstract][Full Text] [Related]
19. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559 [TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft. Adrogue HE; Soltero L; Land GA; Ramanathan V; Truong LD; Suki WN Transplantation; 2006 Aug; 82(4):567-9. PubMed ID: 16926602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]